Bi-specific Antibody PEG Nanoparticle Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PEGylated nanoparticles (PEG-NPs) face challenges in targeting cancer cells effectively due to difficulties in chemical conjugation of antibodies, which can lead to loss of antibody function and heterogeneous orientation, limiting their clinical applicability.
Innovation Solution
Development of humanized bi-specific antibodies that bind to PEG molecules and specific tumor antigens, such as EGFR, HER2, TAG72, CD19, or CD20, to facilitate targeted delivery of therapeutic or imaging agents by forming assemblies with PEGylated substances.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemical conjugation of antibodies to PEG-NPs is performed, then specific targeting and intracellular uptake are improved, but antibody function is lost and heterogeneous orientation occurs
Solution Approach 1:
The patent uses an intermediary approach by designing a bi-specific antibody with distinct binding sites: one site binds to PEG molecules on the nanoparticle surface, while the other site binds to tumor antigens. This intermediary structure (the bi-specific antibody itself) mediates the connection between PEG-NPs and cancer cells without requiring direct chemical conjugation that would compromise antibody function. The antibody acts as a bridge, maintaining its functional integrity while achieving specific targeting.
Solution Approach 2:
The bi-specific antibody is segmented into distinct functional domains: a first antigen binding site for PEG binding and a second antigen binding site for tumor antigen binding. This segmentation allows each domain to perform its specific function independently, with the PEG-binding site maintaining the antibody's structural integrity and the tumor antigen-binding site providing targeting capability, thereby avoiding the heterogeneous orientation problem of chemical conjugation.
2Reliability
If chemical conjugation of antibodies to PEG-NPs is performed, then specific targeting is improved, but reproducible product is difficult to obtain
Solution Approach 1:
The bi-specific antibody serves as a standardized intermediary product that can be manufactured with consistent structure and function. By producing the antibody through recombinant DNA technology rather than chemical conjugation, the manufacturing process achieves better control over the antibody's structure, ensuring reproducible binding sites for both PEG and tumor antigens, thereby improving manufacturing precision and reproducibility.
3Reliability
If chemical conjugation of antibodies to PEG-NPs is performed, then specific targeting is improved, but structure of nano-carriers and encapsulated drugs is altered
Solution Approach 1:
The bi-specific antibody acts as an intermediary that binds to PEG molecules on the nanoparticle surface without requiring chemical modification of the nanoparticle structure itself. This approach maintains the original structure and composition of the PEGylated nanoparticle carrier and its encapsulated drugs, while still achieving specific targeting through the antibody's tumor antigen-binding site.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bi-specific antibodies enhance the targeting and therapeutic efficacy of PEGylated substances by ensuring specific binding to cancer cells, improving drug delivery and imaging capabilities while maintaining antibody function and reproducibility.
Implementation Method 1
a bi-specific antibody (BsAb) that bind to two different epitopes, which are a PEG molecule (e.g., the terminal methoxy or hydroxyl group of the PEG, or the backbone of the PEG) and a target ligand
Implementation Method 2
PEGylated substances, particularly, PEG-NPs can accumulate in tumors due to the enhanced permeability and retention (EPR) effect caused by the abnormal structure of endothelial cells in tumors
Data Source
AI summary
Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppressing the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.